TLR-AD1

**TLR-AD1** is an investigational, personalized autologous tumor-lysate-pulsed dendritic-cell vaccine developed by NovAccess Global and its StemVax Therapeutics subsidiary for malignant glioma, particularly glioblastoma. The product incorporates a Toll-like receptor adjuvant cocktail comprising Pam3Cys, lipopolysaccharide, and CpG oligodeoxynucleotide, intended to activate Toll-like receptors 2, 4, and 9, respectively, promote dendritic-cell maturation and tumor-antigen presentation, and induce an antitumor immune response. The FDA granted orphan-drug designation for treatment of malignant glioma on October 25, 2022; TLR-AD1 remains investigational, has not been FDA-approved, and NovAccess describes it as being at the IND-filing stage. ([accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=906622))

Brand names

StemVax Glioblast

Other names

TLRAD1TLRAD-1TLRAD 1